miR-654-3p predicts the prognosis of hepatocellular carcinoma and inhibits the proliferation,migration,and invasion of cancer cells

Abstract

BACKGROUND:

Increasing evidence reveals that aberrant microRNAs (miRNAs) expression play a crucial role in the tumorigenesis of cancers, including hepatocellular carcinoma (HCC), whereas the role of miR-654-3p in HCC remains unclear. This study aimed to investigate the role of miR-654-3p in HCC.

METHODS:

Real-time quantitative PCR was performed to detect miR-654-3p expression in HCC tissues and cell lines. The association of miR-654-3p expression with clinical characteristics of HCC patients were analyzed. And the prognostic value of miR-654-3p was examined using Kaplan-Meier curve and Cox regression analysis. CCK-8 and Transwell assays were used to observe the effects of miR-654-3p on proliferation, migration, and invasion of HCC cells.

RESULTS:

The miR-654-3p expression was downregulated in both HCC tissues and cell lines, which was significantly associated with lymph node metastasis and TNM stage. Downregulation of miR-654-3p predicted poor prognosis of HCC patients. Overexpression of miR-654-3p inhibited HCC cell proliferation, migration, and invasion, while knockdown of miR-654-3p promoted these cellular behaviors in vitro.

CONCLUSION:

Our study suggested that miR-654-3p expression was downregulated in HCC and might serve as a potential prognostic marker and therapeutic target for the survival of HCC patients. miR-654-3p might exert a suppressor role in HCC through inhibiting tumor cell proliferation, migration, and invasion.

Keywords

Hepatocellular carcinoma invasion miR-654-3p migration prognosis proliferation

1. Introduction

Hepatocellular carcinoma (HCC) is one of the most common and aggressive malignancy and is the third leading cause of cancer-related mortality worldwide [1]. In China, the incidence of HCC is relatively high and accounts for approximately half of the total number of all cases [2, 3]. Till now, despite therapeutic strategies have been widely used and improved, the prognosis of major patients with HCC is still very poor due to early metastasis and high frequency of recurrence [4]. Thus, it is urgently needed to explore more novel cancer-associated molecular biomarkers and therapeutic target for the HCC treatment.

MicroRNAs (miRNAs or miRs) is a cluster of small, single-strand, and noncoding RNAs that can post-transcriptionally regulate the corresponding target gene expression by binding to 3’-UTR regions [5, 6]. Extensive studies have indicated to emerge as essential regulators in various cellular processes, such as differentiation, proliferation, migration, invasion, and apoptosis [7, 8, 9]. MiRNAs have been implicated to function as either oncogenes or tumor suppressor genes during cancer development in various malignancies, including HCC [9, 10, 11]. Previous studies have found that miR-654-3p, a member of the 14q32 region, was aberrantly expressed in several tumors, such as natural killer/T-cell lymphoma [12] and ovarian cancer [13]. In a study by Murilo Vieira Geraldo and co-workers indicated that miR-654-3p played tumor suppressor properties in thyroid cell lines and could regulate some genes expression, such as PTEN, RB1, MMP-9, and FGFR4 [14]. A recent study revealed that several miRNAs were abnormally expressed in HCC and hepatocellular adenomas compared with adjacent normal liver, including miR-654-3p [15]. However, the potential role of miR-654-3p in HCC remains unclear.

In the present study, we firstly explored the expression of miR-654-3p in HCC clinical tissue samples and cell lines by quantitative real-time PCR (qRT-PCR). Then, the association of miR-654-3p expression with clinical characteristics and patients’ prognostic information was evaluated. In addition, the functional role of miR-654-3p in HCC cells was investigated.

2. Materials and methods

2.1 Patients and tissue samples

Paired 117 HCC tissue samples and adjacent normal liver tissue samples were collected from patients who were pathologically diagnosed with HCC and underwent surgery at Affiliated Hospital of Weifang Medical University between June 2010 and December 2013. All fresh tissue samples were immediately put into liquid nitrogen until use. All patients did not receive any therapies prior to surgery. The clinical characteristics of the patients were collected and listed in Table 1. Written informed consent was provided by each patient participated in the study prior to surgery. The study was approved by the Ethics Committee of Affiliated Hospital of Weifang Medical University.

Table 1
The relationship between miR-654-3p expression and clinicopathological parameters of HCC patients

Parameters	Cases ( $n=$ 117)	miR-654-3p expression		$P$
		Low ( $n=$ 60)	High ( $n=$ 57)
Gender				0.361
Male	71	34	37
Female	46	26	20
Age				0.932
$\leqslant$ 55	57	29	28
$>$ 55	60	31	29
Tumor size (cm)				0.166
$\leqslant$ 5	26	32	29
$>$ 5	34	25	24
AFP (ng/mL)				0.183
$\leqslant$ 20	64	31	22
$>$ 20	53	29	31
Differentiation				0.110
Moderate-well	63	28	35
Poor	54	32	22
Lymph node metastasis				0.029*
Negative	66	28	38
Positive	51	32	19
TNM stage				0.004**
I–II	62	24	38
III–IV	55	36	19

* $P<$ 0.05, ** $P<$ 0.01. Low levels of miR-654-3p were associated with positive lymph node metastasis ( $P<$ 0.029) and advanced TNM stage ( $P<$ 0.004). However, miR-654-3p expression was not correlated with other parameters, such as gender, age, tumor size, AFP level, and differentiation ( $P>$ 0.05).

2.2 Cell lines culture and transfection

The human HCC cell lines SK-HEP-1, PLC/PRF/5, Huh7, SNU-182, and one normal liver cell line HL7702 were purchased from Cell Bank of Chinese Academy of Sciences (Shanghai, China). All cells were cultured in DMEM (Thermo Fisher Scientific, IL, USA) containing 10% FBS (Thermo Fisher Scientific, IL, USA) at 37 ${}^{\circ}$ C in a humidified chamber with 5% CO ${}_{2}$ .

The mimic negative control (NC), miR-654-3pmimic, inhibitor NC, and miR-654-3p inhibitor were purchased from GenePharma (Shanghai, China). Lipofectamine 3000 reagent (Invitrogen; Thermo Fisher Scientific, IL, USA) was used for cell transfection following to the manufacturer’s instructions.

Figure 1.

miR-654-3p expression is downregulated in HCC that analyzed using qRT-PCR. A. The relative expression of miR-654-3p was significantly downregulated in HCC tissues compared with adjacent normal tissues. Differences were analyzed using a 2-tailed Student’s t-test. B. The expression of miR-654-3p was significantly lower in HCC cell lines compared with normal liver cells. Differences were analyzed using one-way ANOVA followed by Tukey’s post-hoc test. *** $P<$ 0.001.

2.3 RNA extraction and qRT-PCR

Total RNA was extracted using the TRIzol reagent (Invitrogen; Thermo Fisher Scientific, IL, USA) from HCC tissues or cells according to the manufacturer’s protocol. Then, cDNA was reverse-transcribed using total RNA with the Taqman MicroRNA Reverse Transcription Kit (Applied Biosystems; Thermo Fisher Scientific, IL, USA). The qRT-PCR was performed using a GoTaq qPCR Master Mix (Promega, Madison, WI, USA) on the ABI 7900 System (Bio-Rad) for quantification of miR-654-3p levels. The relative expression levels of miR-654-3p were calculated using 2 ${}^{-\Delta\Delta\text{Ct}}$ method and normalized to U6.

2.4 CCK-8 assay

CCK-8 assay (Dojindo Molecular Technologies, Inc.) was used to evaluate cell proliferative abilities of HCC cell lines after transfected with miR-654-3p mimic or inhibitor. After transfection, the transfected cells were seeded into 96-well plates at a density of 2 $\times$ 10 ${}^{3}$ cell/well. Cells were incubated at 37 ${}^{\circ}$ C with 5% CO ${}_{2}$ for 0, 24, 48, and 72 h, 10 $\mu$ l CCK-8 reagent was added to each well at each time-point. After incubation for a further 2 h at 37 ${}^{\circ}$ C, the optical density (OD) value was detected using a microplate reader (Bio-Tek Company, Winooski, VT, USA) at 450 nm wavelength.

2.5 Transwell migration and invasion assays

Transwell chambers (Millipore, Burlington, MA, USA) were used to assess cell migratory and invasive abilities of HCC cells. For Transwell migration assays, transfected HCC cells (5 $\times$ 10 ${}^{4}$ ) in serum-free culture medium were incubated in the upper chamber, and the lower chamber was filled with complete culture medium containing 10% FBS. For invasion assay, it is similar to migration assay except the upper chamber was pre-coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA). After 24 h of incubation, migrated or invaded cells through the membrane were fixed and stained. The number of cells in five random fields was counted under a microscope.

2.6 Statistical analysis

Each experiment was performed at least three times and data were presented as mean $\pm$ SD. All statistical analysis was performed using the SPSS 20.0 software (SPSS, Chicago, IL, USA) and GraphPad 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Differences were analyzed using $\chi^{2}$ test, Student’s t-test, or one-way ANOVA. Kaplan-Meier curve and Cox regression analysis were used to analyze the prognostic value of miR-654-3p. $P$ less than 0.05 was considered as statistical significance.

3. Results

3.1 The miR-654-3p expression is downregulated in HCC tissues and cell lines

Firstly, we detected miR-654-3p expression levels in 117 pairs of HCC tissues and the adjacent normal tissues by using qRT-PCR. The results showed the relative expression of miR-654-3p was higher in HCC tissues than in normal tissues ( $P<$ 0.001, Fig. 1A). The expression of miR-654-3p was also detected in HCC cell lines. Consistent with HCC tissues, higher miR-654-3p level was observed in HCC cell lines compared to the normal liver cell line ( $P<$ 0.001, Fig. 1B).

3.2 The relationship between miR-654-3p expression and clinical characteristics of HCC patients

To explore whether miR-654-3p expression was associated with HCC progression, the association between its expression and clinical characteristics of HCC patients was analyzed. Then we divided all the patients with HCC into a low miR-654-3p expression group and a high miR-654-3p expression group based on the mean expression level of miR-654-3p. As shown in Table 1, low levels of miR-654-3p were associated with positive lymph node metastasis ( $P<$ 0.029) and advanced TNM stage ( $P<$ 0.004). However, miR-654-3p expression was not correlated with other parameters, such as gender, age, tumor size, AFP level, and differentiation ( $P>$ 0.05).

3.3 Decreased expression of miR-654-3p associated with poor prognosis of patients with HCC

Subsequently, we investigated the prognostic significance of miR-654-3p in HCC patients using Kaplan-Meier curve analysis and log-rank test. As shown in Fig. 2, patients with high levels of miR-654-3p had longer overall survival rates compared with those patients with lower miR-654-3p expression (log-rank $P=$ 0.003). Simultaneously, multivariate Cox regression analysis indicate that low miR-654-3p expression level and advanced TNM stage were independent risk factors for overall survival in HCC patients ( $P<$ 0.05, Table 2). Taken together, these results suggested that miR-654-3p may be a valuable prognostic biomarker for HCC.

Figure 2.

Kaplan-Meier curves for overall survival time. Patients in the low miR-654-3p expression group had a shorter overall survival time compared with those in the high expression group (log-rank $P=$ 0.003).

Table 2

Multivariate Cox analysis for the association between clinical characteristics and overall survival of HCC patients

Characteristics	Multivariate analysis
	HR	95% CI	$P$
miR-654-3p (Low vs. High)	1.891	1.057–3.381	0.032*
Gender (Male vs. Female)	1.722	0.835–3.551	0.141
Age ( $>$ 55 vs. $\leqslant$ 55)	1.051	0.586–1.885	0.867
Tumor size ( $>$ 5 cm vs. $\leqslant$ 5 cm)	1.255	0.678–2.324	0.469
AFP ( $>$ 20 ng/ml vs. $\leqslant$ 20 ng/ml)	1.184	0.686–2.042	0.544
Differentiation (Poor vs. Moderate-well)	1.341	0.747–2.408	0.325
Lymph node metastasis (Positive vs. Negative)	1.784	0.957–3.328	0.069
TNM stage (III–IV vs. I–II)	2.040	1.008–4.130	0.047*

* $P<$ 0.05. Multivariate Cox regression analysis indicate that low miR-654-3p expression level and advanced TNM stage were independent risk factors for overall survival in HCC patients ( $P<$ 0.05).

3.4 Downregulation of miR-654-3p promotes tumor proliferation, migration, and invasion in vitro

To determine the effect of miR-654-3p on HCC cell behavior, we constructed both miR-654-3p overexpression and knockdown HCC cells using miR-654-3p mimics and inhibitors, respectively, in PLC/PRF/5 and HuH7 cells, which had a relative lower miR-654-3p expression level. The qRT-PCR results confirmed transfection efficiency in PLC/PRF/5 and HuH7 cells ( $P<$ 0.001, Fig. 3A). The CCK-8 assay was used to investigate the effect of miR-654-3p transfection on the proliferation of PLC/PRF/5 and HuH7 cells. The results showed that overexpression of miR-654-3p significantly inhibited cellular proliferative abilities of PLC/PRF/5 and HuH7 cells, while knockdown of miR-654-3p promoted cellular proliferative abilities ( $P<$ 0.05, Fig. 3B). In addition, migratory and invasive abilities of HCC cells were detected using Transwell assay. PLC/PRF/5 and HuH7 cells transfected with miR-654-3p mimic exhibited significantly reduced capacities of cell migration and invasion, while cells transfected with miR-654-3p inhibitor showed increased capacities of migration and invasion, compared with those untreated cells ( $P<$ 0.01, Fig. 4A and B).

Figure 3.

Overexpression of miR-654-3p inhibited cell proliferation, while knockdown of miR-654-3p promoted cell proliferation, compared with untreated cells. Differences were analyzed using one-way ANOVA followed by Tukey’s post-hoc test. A. Transfection efficiency of miR-654-3p mimic and inhibitor was confirmed using qRT-PCR. B. CCK-8 assays were performed 0, 24, 48, and 72 h after transfection to determine the proliferation of PLC/PRF/5 and HuH7 cells. * $P<$ 0.05, ** $P<$ 0.01, *** $P<$ 0.001.

Figure 4.

Increased expression of miR-654-3p inhibited cell migration and invasion, while inhibition of miR-654-3p enhanced cell migration and invasion of PLC/PRF/5 and HuH7 cells, compared with untreated cells. Transwell migration (A) and invasion (B) assays were used to explore the effects of miR-654-3p in HCC. Differences were analyzed using one-way ANOVA followed by Tukey’s post-hoc test. ** $P<$ 0.01, *** $P<$ 0.001.

4. Discussion

The present study indicated that miR-654-3p was significantly downregulated in HCC tissues and cell lines compared with matching adjacent normal tissue and normal liver cell lines, respectively. The low expression of miR-654-3p was found associated with positive lymph node metastasis and advanced TNM stage. It also demonstrated that low miR-654-3p expression was an independent predictor of poor prognosis in patients with HCC. Functionally, upregulation of miR-654-3p inhibited the proliferation, migration, and invasion, while knockdown of miR-654-3p reversed the suppressor effects of miR-654-3p overexpression. These findings suggest that miR-654-3p may exert its suppressor roles in HCC.

HCC has become one of the most rapid-growing causes of cancer-related death worldwide because of difficult diagnosis and poor prognosis. Accumulating evidence has highlighted the crucial roles of miRNAs in the regulation of tumor progression, and indicating miRNAs may serve as diagnostic and/or prognostic biomarkers and effective therapeutic targets for cancer treatment [16, 17, 18]. For instance, miR-1285–3p was downregulated in osteosarcoma and inhibited the proliferation and invasion of osteosarcoma cells, suggesting miR-1285–3p might be a potential therapeutic target and prognostic biomarker in osteosarcoma [19]. miR-3691–5p was found upregulated in HCC tissues and cell lines and correlated with poor prognosis, as well as functioned as an oncogene in HCC [20]. Hence, identification of HCC specific miRNAs is still critical for defining novel prognostic biomarker and therapeutic targets for the treatment of HCC.

In this study, by using qRT-PCR, the results showed that the expression of miR-654-3p was downregulated in both HCC tissues and cell lines. Consistent with our findings, Zheng and co-workers using miRNA profiling indicated miR-654-3p was one of the downregulated miRNAs in HCC [15]. Notably, low miR-654-3p expression was found to be associated with positive lymph node metastasis and advanced TNM stages. These results suggested that miR-654-3p may play a suppressor role in the progression of HCC. In addition, downregulation of miR-654-3p significantly predicted poor prognosis. Then, multivariate Cox regression analysis using clinical characteristics and 5-year follow-up information of HCC patients showed that low miR-654-3p expression was an independent prognostic predictor for overall survival of HCC patients. Thus, the results indicated that miR-654-3p may be a novel effective prognostic biomarker for HCC, which served as the prognostic role similarly to several miRNAs in HCC, such as miR-454-3p [21], miR-339-5p [22], and miR-664 [23].

MiRNAs can function as tumor oncogenes or suppressors in human cancers, such as miR-221-5p in renal cell cancer [24], miR-203a-3p in colorectal carcinoma [25], and miR-1204 in HCC [26]. Previous studies have demonstrated that miR-654-3p was downregulated in several cancers including ovarian cancer [13], colorectal cancer [27], and non-small cell lung cancer [28]. For instance, miR-654-3p decreased cell proliferation, migration, and induced reprogramming of metastasis-related genes (such as MMP 9 and IL-1 $\beta$ ), suggesting a tumor suppressor role in papillary thyroid cancer [14]. In prostate cancer, miR-654-3p inhibited proliferation, migration, invasion, and induced apoptosis of PC3 and DU145 cells [29]. Thus, miR-654-3p may serve as a tumor suppressor in several cancers. In this study, we also investigated the functional role of miR-654-3p using CCK-8 assay, Transwell migration and invasion assays. The results showed that overexpression of miR-654-3p inhibited cell proliferation, migration, and invasion, while inhibition of miR-654-3p promoted cell proliferation, migration, and invasion of HCC cells, which is consistent with these above previous studies. In ovarian cancer, functional enrichment analysis showed that miR-654-3p may target VANGL2 and be involved in the Wnt signaling pathway [13]. However, whether miR-654-3p exerts a functional role in HCC also targeting VANGL2 or via some other potential genes remains unclear. Thus, further investigations are needed to uncover the underlying molecular mechanisms. In addition, we will investigate the expression of some migration-related genes in HCC cells after genic modulation of miR-654-3p in future studies.

Taken together, we found that miR-654-3p was downregulated and acted as a tumor suppressor in HCC. Moreover, lower miR-654-3p expression was correlated with shorter overall survival of HCC patients. Overexpression of miR-654-3p inhibited proliferation, migration, and invasion, while inhibition of miR-654-3p promoted proliferation, migration, and invasion of HCC cells. Thus, miR-654-3p may serve as a tumor suppressor and a novel potential prognostic biomarker and therapeutic target for HCC.

Footnotes

Acknowledgments

This work was supported by Shandong Medicine and Health Science Technology Development Project [No. 2017WS849; No. 2017WS777].

Conflict of interest

The authors declare that they have no competing interests.

References

Bray

Ferlay

Soerjomataram

Siegel

R.L.

Torre

L.A.

and Jemal

, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin 68 (2018), 394–424.

Chen

Zheng

Baade

P.D.

Zhang

Zeng

Bray

Jemal

X.Q.

and He

, Cancer statistics in China, 2015, CA Cancer J Clin 66 (2016), 115–132.

Islami

Chen

X.Q.

Lortet-Tieulent

Zheng

Flanders

W.D.

Xia

Thun

M.J.

Gapstur

S.M.

Ezzati

and Jemal

, Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013, Ann Oncol 28 (2017), 2567–2574.

Pan

H.W.

Y.H.

Peng

S.Y.

Liu

S.H.

Lai

P.L.

Lee

P.H.

Sheu

J.C.

Chen

C.L.

and Hsu

H.C.

, Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma, Cancer 98 (2003), 119–127.

Agirre

Martinez-Climent

J.A.

Odero

M.D.

and Prosper

, Epigenetic regulation of miRNA genes in acute leukemia, Leukemia 26 (2012), 395–403.

T.X.

and Rothenberg

M.E.

, MicroRNA, J Allergy Clin Immunol 141 (2018), 1202–1207.

Sun

Xiong

Yan

Chen

and Liu

, Downregulation of microRNA-16-5p accelerates fracture healing by promoting proliferation and inhibiting apoptosis of osteoblasts in patients with traumatic brain injury, Am J Transl Res 11 (2019), 4746–4760.

Zuo

Liu

Huang

and Gong

, MicroRNA-153 inhibits cell proliferation, migration, invasion and epithelial-mesenchymal transition in breast cancer via direct targeting of RUNX2, Exp Ther Med 17 (2019), 4693–4702.

Lin

Zhao

Zhou

Pan

Quan

Peng

Guan

Chen

and Lai

, Oncogene miR-187-5p is associated with cellular proliferation, migration, invasion, apoptosis and an increased risk of recurrence in bladder cancer, Biomed Pharmacother 105 (2018), 461–469.

10.

Z.Y.

Zhang

Z.Z.

Zhang

Q.D.

Zhang

S.J.

Zhou

Zhu

X.Q.

and Zhou

, Upregulated microRNA6713p promotes tumor progression by suppressing forkhead box P2 expression in nonsmallcell lung cancer, Mol Med Rep 20 (2019), 3149–3159.

11.

Hua

Quan

Zhan

Liao

and Lu

, miR-125b-5p inhibits cell proliferation, migration, and invasion in hepatocellular carcinoma via targeting TXNRD1, Cancer Cell Int 19 (2019), 203.

12.

Jang

J.Y.

Kim

C.W.

Huh

Kim

P.J.

and Jeon

Y.K.

, Identification of microRNAs modulated by DNA hypomethylating drugs in extranodal NK/T-cell lymphoma, Leuk Lymphoma (2019), 1–9.

13.

Zhang

Xing

and Yang

, Identification of common differentially-expressed miRNAs in ovarian cancer cells and their exosomes compared with normal ovarian surface epithelial cell cells, Oncol Lett 16 (2018), 2391–2401.

14.

Geraldo

M.V.

Nakaya

H.I.

and Kimura

E.T.

, Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer, Oncotarget 8 (2017), 9597–9607.

15.

Zheng

Sadot

Vigidal

J.A.

Klimstra

D.S.

Balachandran

V.P.

Kingham

T.P.

Allen

P.J.

D’Angelica

M.I.

DeMatteo

R.P.

Jarnagin

W.R.

and Ventura

, Characterization of hepatocellular adenoma and carcinoma using microRNA profiling and targeted gene sequencing, PLoS One 13 (2018), e0200776.

16.

Qadir

M.I.

and Faheem

, miRNA: A Diagnostic and therapeutic tool for pancreatic cancer, Crit Rev Eukaryot Gene Expr 27 (2017), 197–204.

17.

Sartorius

Winkler

Chuturgoon

and Makarova

, The biological and diagnostic role of miRNA’s in hepatocellular carcinoma, Front Biosci (Landmark Ed) 23 (2018), 1701–1720.

18.

Lan

Wang

and Jin

, MicroRNAs as potential biomarkers in cancer: Opportunities and challenges, Biomed Res Int 2015 (2015), 125094.

19.

X.H.

Dai

Shang

H.L.

Zhao

Z.X.

and Hao

Y.D.

, miR-1285-3p is a potential prognostic marker in human osteosarcoma and functions as a tumor suppressor by targeting YAP1, Cancer Biomark 25 (2019), 1–10.

20.

Zhang

and Wan

, miR-3691-5p promotes hepatocellular carcinoma cell migration and invasion through activating PI3K/Akt signaling by targeting PTEN, Onco Targets Ther 12 (2019), 4897–4906.

21.

Jiao

Luo

and Li

, High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma, Cancer Manag Res 11 (2019), 2795–2802.

22.

Wang

Y.L.

Chen

C.M.

Wang

X.M.

and Wang

, Effects of miR-339-5p on invasion and prognosis of hepatocellular carcinoma, Clin Res Hepatol Gastroenterol 40 (2016), 51–56.

23.

Wang

Zhou

Zhang

Wang

Qin

and Zhang

, Overexpression of miR-664 is associated with poor overall survival and accelerates cell proliferation, migration and invasion in hepatocellular carcinoma, Onco Targets Ther 12 (2019), 2373–2381.

24.

Liu

Wang

Wen

Chen

and Lin

, miR-221-5p acts as an oncogene and predicts worse survival in patients of renal cell cancer, Biomed Pharmacother 119 (2019), 109406.

25.

Qian

Gong

Mou

Han

and Zheng

, MicroRNA203a3p is a candidate tumor suppressor that targets thrombospondin 2 in colorectal carcinoma, Oncol Rep (2019).

26.

Wang

Sun

Wang

Yao

Liu

Chen

Liu

and Liu

, miR-1204 promotes hepatocellular carcinoma progression through activating MAPK and c-Jun/AP1 signaling by targeting ZNF418, Int J Biol Sci 15 (2019), 1514–1522.

27.

Alqurashi

Hashimi

S.M.

Alowaidi

Ivanovski

Farag

and Wei

M.Q.

, miR-496, miR-1185, miR-654, miR-3183 and miR-495 are downregulated in colorectal cancer cells and have putative roles in the mTOR pathway, Oncol Lett 18 (2019), 1657–1668.

28.

Zheng

Lian

Yang

and Zeng

, Analysis of microRNA expression profile identifies novel biomarkers for non-small cell lung cancer, Tumori 101 (2015), 104–110.

29.

Formosa

Markert

E.K.

Lena

A.M.

Italiano

Finazzi-Agro

Levine

A.J.

Bernardini

Garabadgiu

A.V.

Melino

and Candi

, MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells, Oncogene 33 (2014), 5173–5182.

miR-654-3p predicts the prognosis of hepatocellular carcinoma and inhibits the proliferation,migration,and invasion of cancer cells

Abstract

BACKGROUND:

METHODS:

RESULTS:

CONCLUSION:

Keywords

1. Introduction

2. Materials and methods

2.1 Patients and tissue samples

Table 1 The relationship between miR-654-3p expression and clinicopathological parameters of HCC patients

2.4 CCK-8 assay

2.5 Transwell migration and invasion assays

2.6 Statistical analysis

3. Results

3.1 The miR-654-3p expression is downregulated in HCC tissues and cell lines

3.2 The relationship between miR-654-3p expression and clinical characteristics of HCC patients

3.3 Decreased expression of miR-654-3p associated with poor prognosis of patients with HCC

Footnotes

Acknowledgments

Conflict of interest

References

Table 1
The relationship between miR-654-3p expression and clinicopathological parameters of HCC patients